ASMBEarnings•globenewswire•
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
Sentiment:Neutral (55)
Summary
– On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179 –
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 6, 2025 by globenewswire